Publication: The unique CARWL score stratifies locally advanced nasopharyngeal cancer patients receiving concurrent chemoradiotherapy into risk groups for radiation-induced trismus
dc.contributor.coauthor | Somay, Efsun | |
dc.contributor.coauthor | Bascil, Sibel | |
dc.contributor.coauthor | Ozturk, Duriye | |
dc.contributor.coauthor | Topkan, Erkan | |
dc.contributor.department | KUH (Koç University Hospital) | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Durankuş, Nilüfer Kılıç | |
dc.contributor.kuauthor | Selek, Uğur | |
dc.contributor.kuauthor | Şenyürek, Şükran | |
dc.contributor.schoolcollegeinstitute | KUH (KOÇ UNIVERSITY HOSPITAL) | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2025-03-06T20:58:05Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Purpose To determine the utility of the novel CARWL score, which integrates C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL), in stratifying the locally advanced nasopharyngeal carcinoma (LA-NPC) patients into significantly different radiation-induced trismus (RIT) risk groups following definitive C-CRT. Patients and methods This retrospective study analyzed the medical records of 286 LA-NPC patients who received C-CRT between January 2010 and December 2022. The maximum mouth opening (MMO) was measured before the C-CRT, at 1, 3, 6, 9, and 12 months, and every 6 months after that during the follow-up. Additionally, the CAR value just before the commencement of C-CRT and SWL defined as a weight loss > 5% in the preceding six months were documented for each patient. RIT was defined as a MMO <= 35 mm. Results The optimal CAR cut-off was 3.03 (area under the curve: 87.3%;sensitivity: 82.6%;specificity: 80.9%, J-index: 0.635), using receiver operating characteristic (ROC) curve analysis, with RIT incidence being the event. We stratified the patients into three CARWL score groups. CARWL-0: CAR < 3.0 and WL <= 5.0% (N = 92), CARWL-1: CAR < 3.0 and WL > 5.0% or CAR >= 3.0 (N = 99), and WL <= 5.0% and CARWL-2: CAR > 3.0 and WL > 5.0% (N = 95). The incidence of RIT increased significantly across CARWL score groups (8.7% for CARWL-0, 23.2% for CARWL-1, and 44.2% for CARWL-2;P < 0.001). Conclusion The current study indicated that the novel CARWL scoring system is efficient in precisely stratifying LA-NPC patients into distinct RIT risk groups after C-CRT. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.identifier.doi | 10.1007/s12672-024-01441-y | |
dc.identifier.eissn | 2730-6011 | |
dc.identifier.issue | 1 | |
dc.identifier.quartile | Q2 | |
dc.identifier.scopus | 2-s2.0-85206383030 | |
dc.identifier.uri | https://doi.org/10.1007/s12672-024-01441-y | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/27355 | |
dc.identifier.volume | 15 | |
dc.identifier.wos | 1336886700004 | |
dc.keywords | Radiation-induced trismus | |
dc.keywords | Chemoradiotherapy | |
dc.keywords | C-reactive protein-to-albumin ratio | |
dc.keywords | Significant weight loss | |
dc.keywords | Nasopharyngeal carcinoma | |
dc.language.iso | eng | |
dc.publisher | Springer | |
dc.relation.ispartof | DISCOVER ONCOLOGY | |
dc.subject | Oncology | |
dc.subject | Endocrinology | |
dc.title | The unique CARWL score stratifies locally advanced nasopharyngeal cancer patients receiving concurrent chemoradiotherapy into risk groups for radiation-induced trismus | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Selek, Uğur | |
local.contributor.kuauthor | Durankuş, Nilüfer Kılıç | |
local.contributor.kuauthor | Şenyürek, Şükran | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit1 | KUH (KOÇ UNIVERSITY HOSPITAL) | |
local.publication.orgunit2 | KUH (Koç University Hospital) | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isParentOrgUnitOfPublication | 055775c9-9efe-43ec-814f-f6d771fa6dee | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 055775c9-9efe-43ec-814f-f6d771fa6dee |